Viveve Medical (Viveve Medical) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Viveve Medical's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.00.

Viveve Medical's long-term debt to total assets ratio declined from Sep. 2021 (0.16) to Sep. 2022 (0.00). It may suggest that Viveve Medical is progressively becoming less dependent on debt to grow their business.

Viveve Medical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Viveve Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical LT-Debt-to-Total-Asset Chart

Viveve Medical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.80

0.65

0.15

0.30

0.20

Viveve Medical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.20	-	-	-

Viveve Medical LT-Debt-to-Total-Asset Calculation

Viveve Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	5.124	/	25.913
	=	0.20

Viveve Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )	/	Total Assets (Q: Sep. 2022 )
	=	0	/	12.154
	=	0.00

Viveve Medical (OTCPK:VIVE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Viveve Medical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Viveve Medical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Viveve Medical (Viveve Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112

Website

https://www.viveve.com

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.

Executives

Presnell Sharon Collins	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta	director	1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin	officer: Chief Financial Officer	PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson	officer: CBO & President	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller	director, officer: CEO and Director	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico	director, 10 percent owner	16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney	director, 10 percent owner	PO BOX 7414, JACKSON WY 83002